A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Nab-paclitaxel
Sponsor: Bristol-Myers Squibb